[Primary small bowel adenocarcinoma]
Related Experiment Video
Updated: Jun 24, 2026
Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids
Published on: October 14, 2019
Jaime Ruiz-Tovar1, Enrique Martínez-Molina, Vicente Morales
1Departamento de Cirugía General y del Aparato Digestivo, Hospital Universitario Ramón y Cajal, Madrid, España. jruiztovar@gmail.com
Introduction:
Primary small bowel adenocarcinoma is an uncommon tumour, with non-specific symptoms that cause a delay in the diagnosis and consequently a worse outcome for the patient. We analyse our experience in the management of this disease.
Material And Method:
We performed a retrospective study of our experience with 17 patients diagnosed with primary small bowel adenocarcinoma, excluding all the cases suggesting secondary involvement of the small bowel from an adenocarcinoma in other locations.
Results:
We analysed 9 females (53%) and 8 males (47%) with a mean age of 61.8 years. Tumour location was duodenum (8 cases), jejunum (5) and ileum (4). Those with duodenal tumours underwent 4 pancreaticoduodenectomies, 3 gastroenterostomies and 1 diagnostic biopsy; 6 bowel resections with lymphadenectomy, 2 en-bloc resections and 1 by-pass were performed on those with jejuno-ileal tumours. There were complications in 3 patients (18%). General survival was 18 months; in duodenal and jejunal tumours it was 15 months vs. 58 in ileal ones (p = 0.048). Survival was 48 months in the absence of lymph node metastases vs. 11 in those with (p = 0.067). In those tumours infiltrating the retroperitoneum, survival was 15 months compared to 23 when not affected (p = 0.09).
Conclusions:
Curative treatment consists of small bowel resection. Retroperitoneal infiltration was a non-resectability criterion in our series. Ileal location is associated with a better outcome. Advanced stages, lymph node metastases, non-resected cases and retroperitoneal infiltration tended to be associated with a poor prognosis in our group.
